Cancer Research Meeting Calendar  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zheng, G.
Right arrow Articles by Tykocinski, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zheng, G.
Right arrow Articles by Tykocinski, M. L.
[Cancer Research 61, 8127-8134, November 15, 2001]
© 2001 American Association for Cancer Research


Carcinogenesis

Induction of Antitumor Immunity via Intratumoral Tetra-Costimulator Protein Transfer1

Guoxing Zheng, Aoshuang Chen, Raymond E. Sterner, Paul J. Zhang, Tao Pan, Nadya Kiyatkin and Mark L. Tykocinski2

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 [G. Z., A. C., R. E. S., P. J. Z., N. K., M. L. T.], and Department of Pathology, Case Western Reserve University, Cleveland, Ohio 45216 [T. P.]

Our group recently described a novel two-step Fc{gamma}1 fusion protein transfer method, which entails the docking of Fc{gamma}1 fusion proteins onto cells precoated with chemically palmitated protein A (pal-prot A). In the present study, we have adapted this protein transfer method, originally used in an ex vivo context, for in situ tumor cell engineering, and in so doing, we have evaluated its utility for the induction of antitumor immunity via combinatorial costimulator protein transfer on to tumor cell surfaces. The feasibility of "painting" cells with preformed conjugates of a murine B7–1 costimulator derivative, B7–1·Fc{gamma}1, and pal-prot A in a single step was first established ex vivo. Next, B7–1·Fc{gamma}1:pal-prot A transfer was accomplished in vivo by directly injecting the preformed conjugates into highly aggressive L5178Y-R lymphomas grown intradermally in syngeneic mice. The presence of cell surface-associated B7–1 epitopes on cells of the injected tumors was documented by flow cytometric analysis of cells recovered subsequently from the injected tumors. B7–1·Fc{gamma}1, along with Fc{gamma}1 fusion protein derivatives of three additional costimulators (Fc{gamma}1·4–1BBL, CD48·Fc{gamma}1, and Fc{gamma}1·CD40L) geared toward a variety of immune effectors, were together preconjugated with pal-prot A and injected directly into tumor beds. Significantly, this "tetra-costimulator" combination, delivered intratumorally, induced complete tumor regression in ~45% of treated mice, whereas control injections of pal-prot A alone had no therapeutic effect. Furthermore, there was evidence for systemic antitumor immunity in that tumor-specific CTLs were detected in spleens recovered from cured mice, and these mice were uniformly protected against tumor rechallenge at distant tumor sites. Hence, combinatorial costimulator transfer, coupled to intratumoral delivery, may have special advantages for the induction of antitumor immunity.




This article has been cited by other articles:


Home page
J. Immunol.Home page
S. Liu, D. R. Breiter, G. Zheng, and A. Chen
Enhanced Antitumor Responses Elicited by Combinatorial Protein Transfer of Chemotactic and Costimulatory Molecules
J. Immunol., March 1, 2007; 178(5): 3301 - 3306.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Chen, S. Liu, D. Park, Y. Kang, and G. Zheng
Depleting Intratumoral CD4+CD25+ Regulatory T Cells via FasL Protein Transfer Enhances the Therapeutic Efficacy of Adoptive T Cell Transfer
Cancer Res., February 1, 2007; 67(3): 1291 - 1298.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Liu, B. A. Foster, T. Chen, G. Zheng, and A. Chen
Modifying Dendritic Cells via Protein Transfer for Antitumor Therapeutics
Clin. Cancer Res., January 1, 2007; 13(1): 283 - 291.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Zheng, S. Liu, P. Wang, Y. Xu, and A. Chen
Arming Tumor-Reactive T Cells with Costimulator B7-1 Enhances Therapeutic Efficacy of the T Cells.
Cancer Res., July 1, 2006; 66(13): 6793 - 6799.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Liu, P. Hu, L. A. Khawli, and A. L. Epstein
Combination B7-Fc Fusion Protein Treatment and Treg Cell Depletion Therapy
Clin. Cancer Res., December 1, 2005; 11(23): 8492 - 8502.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Zheng, B. Wang, and A. Chen
The 4-1BB Costimulation Augments the Proliferation of CD4+CD25+ Regulatory T Cells
J. Immunol., August 15, 2004; 173(4): 2428 - 2434.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.